Triclabendazole for Humans: Egaten Dose by Weight, Side Effects and How to Get It in the US
SafeRxPills Pharmacy Team
Editorial team at SafeRxPills. Articles are written and checked against regulatory drug labelling (DailyMed, FDA, EMA) and published literature.

Buy Triclabendazole Online in the USA: 2026 Fascioliasis Treatment Guide | SafeRxPills — pharmacy guide
In this article (28 sections)
Triclabendazole is the medicine used to treat fascioliasis, an infection with the Fasciola liver fluke. In the US it is sold as Egaten, a 250 mg scored tablet from Novartis that the FDA approved in February 2019 for patients aged 6 years and older. Treatment is short: two doses on one day, each worked out from body weight and taken with food.
This guide covers what triclabendazole for humans is approved to treat, how the dose is calculated, how many tablets a course takes at different weights, the label's QT warning and interaction rules, the side effects and cure rates from the label studies, reports of treatment failure, how people in the US get it, and what the FDA says about importing medicines. We sell Indian triclabendazole tablets, so we have a commercial interest. Every number below comes from the FDA label, FDA databases, the CDC, the World Health Organization, Novartis, CMS, a published study listed under Sources, or our own price list. Triclabendazole should only be taken after a doctor has confirmed the infection.
The short answer
- What it treats (US label): fascioliasis in patients 6 years of age and older. Fascioliasis is infection with the liver flukes Fasciola hepatica or Fasciola gigantica.
- US label dose: 2 doses of 10 mg/kg given 12 hours apart, taken with food. That is 20 mg/kg in total on one day.
- Tablets: each 250 mg tablet splits into two 125 mg halves, and the label says to round the dose upwards. A 70 kg adult takes 3 tablets per dose, 6 for the day (computed below).
- Do not take it if you are allergic to triclabendazole, to other benzimidazole medicines or to any tablet ingredient (contraindicated).
- Main warning: Egaten prolongs the QTc interval of the heart rhythm. ECG monitoring is advised for people with QT risk factors, liver impairment, or medicines that prolong QT or block CYP1A2.
- How well it works: in the label studies, 95.5% of patients given 20 mg/kg in two doses had no Fasciola eggs in stool at day 60.
- In the US: Egaten is a prescription drug. Drugs@FDA lists no approved generic.
What triclabendazole is
Triclabendazole is an anthelmintic, a medicine that acts against parasitic worms. Chemically it is a benzimidazole derivative, the same broad family as albendazole and mebendazole, but its use is much narrower. The US label describes it as "an anthelmintic against Fasciola species", and its only US indication is fascioliasis.
The label says the way it works "is not fully elucidated." Studies in the laboratory and in infected animals suggest that triclabendazole and its two active metabolites (the sulfoxide and the sulfone) are absorbed through the outer surface of the worm, the tegument. This lowers the worm's resting membrane potential and blocks tubulin function and protein and enzyme synthesis, which stops the worm moving and damages its surface. The label states that triclabendazole and its metabolites are active against both immature and mature worms of Fasciola hepatica and Fasciola gigantica.
That activity against the young, migrating stage matters because fascioliasis has an early phase in which flukes travel through the liver before they settle in the bile ducts. The CDC calls triclabendazole "the drug of choice for treatment of fascioliasis."
What fascioliasis is and how people catch it
Fasciola is a liver fluke that lives in the liver and bile ducts of sheep, cattle, goats and other plant-eating animals, and it can infect people. According to the CDC, people get infected by eating raw watercress or other freshwater plants that carry the parasite's larvae, or by drinking contaminated water or eating vegetables washed or irrigated with it. It does not spread from person to person.
The CDC lists fascioliasis in more than 70 countries, especially where sheep, cattle or goats are raised. Fasciola hepatica occurs on every continent except Antarctica, while Fasciola gigantica occurs only in parts of Africa and Asia. The WHO fact sheet on foodborne trematode infections reports high burdens in Latin America and the Middle East. Local infection in the US is rare: the CDC notes a few reported cases in Hawaii, California and Florida, and says most US cases occurred in immigrants infected in countries where the disease occurs.
The infection has two phases. In the acute phase, which the CDC says lasts up to about 3 to 4 months, immature flukes move through the intestinal wall and the liver. The WHO describes symptoms such as fever, nausea, a swollen liver, skin rashes and severe abdominal pain. In the chronic phase the adult flukes live in the bile ducts and lay eggs. Symptoms can include intermittent pain, jaundice, anaemia, pancreatitis and gallstones, and the CDC describes episodes of biliary obstruction. On limited data, the CDC says adult flukes may live 5 to 10 years or longer in people, with some reports up to 13.5 years.
How fascioliasis is diagnosed before treatment
Testing comes before treatment. The CDC lists stool examination for Fasciola eggs as the most widely used approach, with blood tests and imaging (ultrasound, CT or MRI) as support. Timing affects which test works:
| Test | What the CDC says about timing and limits |
|---|---|
| Stool microscopy for eggs | Egg production typically does not start until about 3 to 4 months after exposure; more than one stool sample may be needed in light infections |
| Antibody (serology) test | Antibodies may become detectable 2 to 4 weeks after exposure; CDC runs an immunoblot for IgG antibody to the FhSAP2 antigen |
| Eosinophil count, imaging | Supportive evidence; imaging or tissue samples can sometimes show the flukes |
Two pitfalls matter for treatment. Fasciola eggs are hard to tell apart from the eggs of Fasciolopsis buski, an intestinal fluke that is treated with praziquantel, while praziquantel "typically is not effective therapy for fascioliasis." And eating infected animal liver can put non-infective Fasciola eggs in the stool (false fascioliasis); the CDC suggests a liver-free diet for several days before repeating the stool test.
What the US label approves triclabendazole for
The current Egaten US prescribing information (Novartis, posted on DailyMed in June 2026) has a single indication: "the treatment of fascioliasis in patients 6 years of age and older." Safety and effectiveness have not been established in children younger than 6.
The label does not cover any other worm infection. Triclabendazole is not a general dewormer for roundworm, pinworm, hookworm or tapeworm, which are treated with other medicines such as albendazole, mebendazole or praziquantel depending on the parasite. Our intestinal worm treatment guide covers those infections. For an overview of gut parasites and how they are treated, see our intestinal parasites condition page.
Paragonimiasis: a WHO use outside the US label
The WHO Model List of Essential Medicines has listed triclabendazole since 1997 for both fascioliasis and paragonimiasis (lung fluke infection, caught from raw or undercooked freshwater crabs and crayfish). The WHO listing is a 250 mg scored tablet.
The WHO fact sheet gives these regimens, which differ from the US label in places:
| Infection and setting | WHO recommended triclabendazole dose |
|---|---|
| Fascioliasis, individual case management | 10 mg/kg as a single dose; 20 mg/kg in two divided doses 12 to 24 hours apart in case of treatment failure |
| Fascioliasis, preventive chemotherapy in clustered communities | 10 mg/kg as a single dose, every 12 months |
| Paragonimiasis, individual case management | 2 x 10 mg/kg in the same day (praziquantel is the alternative) |
| Paragonimiasis, preventive chemotherapy | 20 mg/kg as a single dose, every 12 months |
In the US, the approved fascioliasis regimen is the two-dose 20 mg/kg day, not the WHO single 10 mg/kg dose. Paragonimiasis is not on the US label.
US label dose: two doses of 10 mg/kg, 12 hours apart
The label's dosing section reads: "The recommended dose of EGATEN is 2 doses of 10 mg/kg given 12 hours apart in patients 6 years of age and older." The dose is taken by mouth with food. The 250 mg tablets "are functionally scored and divisible into two equal halves of 125 mg," and "if the dosage cannot be adjusted exactly, round the dose upwards."
The CDC's clinical page gives the same regimen for patients at least six years of age: two doses of 10 mg/kg, 12 hours apart, taken with food to improve absorption. The whole course is one day.
How many 250 mg tablets per dose, by weight
We worked out the number of tablets from the label rule: 10 mg per kg of body weight per dose, rounded up to the next 125 mg half tablet. These are computed examples, not a prescription; your prescriber sets the dose from your measured weight.
| Body weight | 10 mg/kg dose | Rounded up to | Tablets per dose | Tablets for the day (2 doses) |
|---|---|---|---|---|
| 20 kg | 200 mg | 250 mg | 1 | 2 |
| 30 kg | 300 mg | 375 mg | 1.5 | 3 |
| 40 kg | 400 mg | 500 mg | 2 | 4 |
| 50 kg | 500 mg | 500 mg | 2 | 4 |
| 60 kg | 600 mg | 625 mg | 2.5 | 5 |
| 70 kg | 700 mg | 750 mg | 3 | 6 |
| 80 kg | 800 mg | 875 mg | 3.5 | 7 |
| 90 kg | 900 mg | 1,000 mg | 4 | 8 |
| 100 kg | 1,000 mg | 1,000 mg | 4 | 8 |
Egaten is supplied in blister packs of 4 tablets, so adults above about 50 kg need more than one pack for one treatment day.
How to take the tablets
- With food. The label says to take Egaten orally with food.
- Whole, halved or crushed. Tablets can be swallowed whole or divided in half and taken with water, or crushed and mixed with applesauce. The crushed tablet in applesauce is stable for up to 4 hours.
- Timing. The second dose comes 12 hours after the first.
- Storage. Keep the tablets in the original container below 30°C (86°F).
Egaten tablets are pale red, speckled and capsule shaped, debossed on one side and scored on both sides. Each contains 250 mg of triclabendazole.
Why food matters: what the label's absorption data show
Food raises the amount of drug that reaches the blood. When a single 10 mg/kg dose was taken with a meal of about 560 kcal, peak levels (Cmax) and total exposure (AUC) of triclabendazole rose about 3-fold, and those of the active sulfoxide metabolite about 2-fold, compared with fasting.
| Measure (label section 12.3) | Triclabendazole | Sulfoxide metabolite | Sulfone metabolite |
|---|---|---|---|
| Peak level after 10 mg/kg with a meal (µmol/L) | 1.16 | 38.6 | 2.29 |
| AUC (µmol·h/L) | 5.72 | 386 | 30.5 |
| Elimination half-life (hours) | about 8 | about 14 | about 11 |
| Protein binding in plasma | 96.7% | 98.4% | 98.8% |
Median time to peak was 3 to 4 hours for the parent drug and the sulfoxide. In laboratory studies, triclabendazole is mainly converted to its active sulfoxide by the liver enzyme CYP1A2 (about 64%), which is why CYP1A2 blockers appear in the label's QT warning.
Who should not take triclabendazole
The label has one contraindication: "EGATEN is contraindicated in patients with known hypersensitivity to triclabendazole and/or to other benzimidazole derivatives or to any of the excipients in EGATEN." Benzimidazole derivatives include albendazole and mebendazole, so a known allergy to those medicines means triclabendazole is contraindicated; tell your prescriber.
The inactive ingredients listed on the label are colloidal silicon dioxide, iron oxide red, lactose monohydrate, maize starch, magnesium stearate and methylhydroxyethylcellulose.
QT prolongation: the label's main warning
The label's warning reads: "EGATEN prolongs the QTc interval." QTc is a measure of the heart's electrical recovery time, and a long QTc can lead to dangerous rhythm problems. The label adds that the size of the effect "can increase with increasing treatment duration," and that CYP1A2 inhibitors or liver impairment may raise drug levels and so may increase the risk.
| Regimen in the QT study (healthy volunteers) | Largest placebo-corrected mean QTc increase | Upper confidence limit |
|---|---|---|
| 10 mg/kg twice daily for 1 day (the recommended dose) | 9.2 msec | 12.2 msec |
| 10 mg/kg twice daily for 3 days (3 times the approved duration) | 21.7 msec | 24.7 msec |
The label says to monitor the ECG in patients with a history of QTc prolongation or symptoms of a long QT interval, with electrolyte imbalance such as low potassium, who take drugs known to prolong the QTc interval, who take CYP1A2 inhibitors, or who have hepatic impairment. "If signs of cardiac arrhythmia occur during treatment with EGATEN, stop the treatment and monitor ECG." In the one reported overdose, about 54 mg/kg (about 2.7 times the recommended dose), the symptom was nausea; the label advises ECG monitoring after an overdose.
Drug interactions: CYP1A2 inhibitors and CYP2C19 substrates
No clinical drug interaction studies have been done with triclabendazole. The label flags two areas from laboratory data:
- CYP1A2 inhibitors. Because CYP1A2 is the main route for converting triclabendazole, medicines that block it may raise exposure and the QT risk; the label calls for ECG monitoring in people taking them.
- CYP2C19 substrates. Triclabendazole and its metabolites inhibit several liver enzymes in the laboratory, with the highest potential for CYP2C19. Levels of drugs cleared by CYP2C19 may rise, though the label expects this to be "transient" given the short half-life and one-day course. For CYP2C19 drugs that need blood level monitoring, the label says to re-check the level after triclabendazole is stopped.
Bring a full medicine list, including supplements, to the prescriber so these can be checked before the treatment day.
Side effects in the label studies
The label pools safety data from 208 adult and pediatric patients aged 5 years and older in 6 fascioliasis studies. Table 1 of the label splits them into two groups: 186 patients who received a single 10 mg/kg dose (not the approved regimen) and 28 who received 20 mg/kg in two divided doses, which matches the approved total. Divided doses in these studies were given 6 to 48 hours apart.
| Adverse reaction (label Table 1) | 10 mg/kg once, N=186 | 20 mg/kg in two doses, N=28 |
|---|---|---|
| Abdominal pain | 105 (56%) | 26 (93%) |
| Hyperhidrosis (sweating) | 42 (23%) | 7 (25%) |
| Vertigo | 16 (9%) | 0 |
| Nausea | 15 (8%) | 5 (18%) |
| Urticaria (hives) | 12 (7%) | 3 (11%) |
| Vomiting | 11 (6%) | 2 (7%) |
| Headache | 11 (6%) | 4 (14%) |
| Dyspnea (shortness of breath) | 9 (5%) | 0 |
| Pruritus (itching) | 8 (4%) | 1 (4%) |
| Decreased appetite | 6 (3%) | 5 (18%) |
| Jaundice | 4 (2%) | 0 |
| Diarrhea | 0 | 2 (7%) |
Other reactions in the table include asthenia, musculoskeletal chest pain, cough, chest pain, pyrexia and chest discomfort, each at 2% to 4% in the single-dose group. The label lists constipation, biliary colic, arthralgia, back pain, spinal pain and chromaturia (discolored urine) at 2% or less. These studies had no placebo group, and the two dose groups are of very different sizes.
Biliary colic, jaundice and liver enzymes
Pain after treatment is common, and part of it may come from the infection. The label says that "some adverse reactions associated with triclabendazole treatment in fascioliasis, e.g., abdominal pain, biliary colic, and jaundice, could be secondary to the infection and may be more frequent and/or severe in patients with a heavy worm burden." The current US label does not list biliary obstruction as a separate warning, but the CDC notes that the large size of the parasite "can predispose to biliary obstruction during the chronic phase," and that some patients with biliary tract obstruction may need the flukes removed, for example by ERCP.
Liver tests can move too. Up to one third of patients in the studies had raised liver enzymes before treatment, which generally improved afterwards. Among those with normal values at baseline, the label reports post-treatment rises in:
| Liver test | Share with a new rise after treatment |
|---|---|
| Bilirubin | 6.8% |
| AST | 4.5% |
| Alkaline phosphatase (ALP) | 4.2% |
| ALT | 3% |
Severe or worsening pain on the right side of the abdomen, yellowing of the skin or eyes, fever, or a racing or irregular heartbeat after treatment should be reported to a doctor promptly.
How well it works: cure rates in the label studies
The label's development program included 6 non-randomized, open label studies in Cuba, Bolivia, Peru, Chile and Iran, with 245 patients with stool-confirmed fascioliasis. Cure was defined as no Fasciola eggs in the stool by the Kato-Katz method at day 60. Cure rose with the total dose:
| Total triclabendazole dose | Day 60 cure rate | 95% confidence interval | US approval status |
|---|---|---|---|
| 5 mg/kg | 50% | 27% to 73% | Not approved |
| 10 mg/kg | 80% | 73% to 86% | Not approved |
| 15 mg/kg | 88% | 64% to 99% | Not approved |
| 20 mg/kg in 2 doses (approved total) | 95.5% | 77% to 100% | Approved total |
For comparison, the label cites a separate study in which patients given an inadequate, non-triclabendazole treatment had an estimated cure rate of 22%. It is a different study, so it is not a head-to-head result.
The label also describes one randomized trial in Vietnam. One hundred patients aged 9 to 74 years with acute symptomatic fascioliasis received either triclabendazole (two 10 mg/kg doses 12 hours apart with food) or oral artesunate (4 mg/kg once daily for 10 days). At 3 months, 92% of the triclabendazole group and 76% of the artesunate group reported no clinical symptoms (difference 16%, p = 0.035).
Treatment failure and resistance
The label notes that "resistance to triclabendazole has been reported" after marketing, and that "the clinical significance of triclabendazole resistance in humans is not established." Published reports from the Cusco region of Peru show what failure can look like.
| Treatment round (146 children, Cusco, Peru) | Parasitologic cure |
|---|---|
| 1st treatment | 55% |
| 2nd treatment | 38% |
| 3rd treatment | 30% |
| 4th treatment | 23% |
In that retrospective cohort (Morales and colleagues, Emerging Infectious Diseases, 2021), children passing Fasciola eggs were given directly observed 10 mg/kg doses and checked by stool microscopy 1 to 4 months after each round; 17 children (11.6%) were still not cured after 4 treatments. Higher baseline egg counts and lower socioeconomic status were linked with failure. An earlier case series from the same region (Cabada and colleagues, 2016) described 7 patients, mostly symptomatic adults, who kept passing eggs after several courses of two 10 mg/kg doses. These are results from one highland region with heavy, repeated exposure, not from the US label studies, but they are a reason for a follow-up stool test after treatment.
If triclabendazole is not an option: what the CDC says
The CDC's clinical page lists one alternative and rules out another:
- Nitazoxanide: "Based on limited data, nitazoxanide might be effective therapy in some patients," at 500 mg twice a day for seven days for adults, taken with food. Our nitazoxanide 500 mg guide covers that medicine.
- Praziquantel: it "typically is not active against Fasciola parasites and therefore not recommended," even though it treats most other flukes. See our praziquantel for humans guide for the flukes it does treat.
- Procedures: some patients with biliary tract obstruction may need the adult flukes removed, for example by ERCP.
Pregnancy, breastfeeding, children and older adults
- Pregnancy: the label says there are no available data on Egaten use in pregnant women to inform a drug-associated risk. Rat and rabbit studies at about 0.3 to 1.6 times the maximum recommended human dose showed no increase in fetal malformations.
- Breastfeeding: there are no data on triclabendazole in human milk. It has been found in goat milk, and the label says it is likely to be present in human milk, so the benefit of breastfeeding is weighed against the mother's need for treatment.
- Children: approved from 6 years of age. In a small pharmacokinetic study, sulfoxide exposure was 20% lower in 7 children aged 9 to 15 than in older patients, a difference that was not statistically significant.
- Older adults, kidney and liver disease: the studies had too few patients aged 65 and over, and Egaten has not been studied in renal or hepatic impairment. Liver impairment is one of the label's reasons for ECG monitoring.
Is livestock triclabendazole the same thing?
No. Bulk triclabendazole powders appear on DailyMed, the US label database. The listings we checked on 27 October 2026 (from Maeda Inc, AX Pharmaceutical Corp and Bluebay Shandong) are bulk powders, and the two we opened are categorized as "BULK INGREDIENT - ANIMAL DRUG." They are raw material, not finished human tablets with a human dose. Do not use livestock or bulk products to treat a person: the human dose depends on accurate tablet strength and on the warnings in the human label.
Egaten in the US: approval, maker and generic status
| Item | What Drugs@FDA and the label show |
|---|---|
| Application | NDA 208711, sponsor Novartis |
| Approval date | 13 February 2019, priority review, new molecular entity, orphan designation |
| Product | EGATEN (triclabendazole) 250 mg tablet, oral |
| Marketing status | Prescription ("Rx only" on the carton) |
| Pack | Blister pack of 4 tablets, NDC 0078-0937-91 |
| Latest labeling change | Supplement approved 17 February 2022 (QT prolongation warning updated 2/2022) |
| Approved generics | None found: an openFDA search for triclabendazole on 27 October 2026 returned only NDA 208711 |
In its approval announcement of 13 February 2019, Novartis described Egaten as "the only FDA-approved drug for people with this disease," and said the approval triggered a priority review voucher because the FDA recognizes fascioliasis as a neglected tropical disease.
How people in the US get triclabendazole
Egaten is a prescription medicine, so the usual path is a doctor's diagnosis and a prescription filled through a pharmacy. It is a rarely used drug, and we could not find a current primary source that describes a special US access program for it, so check directly with the pharmacy and the maker. The label lists Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, as distributor and gives 1-888-669-6682 for information on Egaten.
Two things that are sometimes said about access do not match what we found today. The CDC Drug Service formulary page, which describes the products CDC supplies to treating physicians, does not list triclabendazole. And the CMS NADAC survey of US pharmacy purchase prices had no rows for Egaten or triclabendazole in its 2024, 2025 or 2026 files, so there is no federal benchmark for what US pharmacies pay. Ask the pharmacy and your insurer for the actual cost before the prescription is filled.
The WHO donation program
Novartis has provided Egaten free of charge through the WHO since 2005. Its donations page says the program has supplied about 7.2 million tablets, helping to treat around 2.4 million people with fascioliasis in more than 40 countries, and that in 2025 Novartis extended the agreement with the WHO until 2030, covering fascioliasis and paragonimiasis.
The WHO fact sheet explains how it works: "WHO collects applications from ministries of health and medicines are shipped free of charge." The donation goes to national programs in endemic countries. It is not a route for an individual patient in the US to obtain the medicine.
Buying triclabendazole from abroad: what the FDA says
Triclabendazole tablets made in India are not FDA approved. The FDA's personal importation page says: "In most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use because these products purchased from other countries often have not been approved by the FDA for use and sale in the U.S. If a drug is approved for use in another country but is an unapproved new drug in the U.S. it is illegal to import."
The same page lists narrow situations in which FDA staff "may consider a more permissive decision" for a prescription drug: the product is for a serious condition for which effective treatment may not be available domestically, there is no known commercialization or promotion to people in the US, the product does not represent an unreasonable risk, the consumer affirms in writing that it is for personal use, the quantity is generally not more than a three month supply, and the buyer names the US doctor responsible for treatment or shows the treatment began abroad. Egaten is FDA approved and marketed in the US, so a domestic option exists. Check your own situation, and the rules where you live, before ordering any medicine from another country.
Triclabend 250 mg and 500 mg on SafeRxPills
We sell two Indian triclabendazole tablets made by Kachhela Medex Pvt. Ltd.: Triclabend 250 mg and Triclabend 500 mg. They are not FDA approved, and we found no published study comparing them with Egaten, so treat them as the same active ingredient, not as an identical product. The label's half-tablet dosing relies on Egaten's 125 mg score line; check whether your tablets are scored and ask your prescriber how to make up the dose. Prices as of 27 October 2026:
| Product and pack | Price | Per tablet |
|---|---|---|
| Triclabend 250 mg, 40 tablets | $66.00 | $1.65 |
| Triclabend 250 mg, 80 tablets | $118.00 | $1.48 |
| Triclabend 250 mg, 160 tablets | $200.00 | $1.25 |
| Triclabend 250 mg, 320 tablets | $340.00 | $1.06 |
| Triclabend 500 mg, 50 tablets | $100.00 | $2.00 |
| Triclabend 500 mg, 100 tablets | $180.00 | $1.80 |
| Triclabend 500 mg, 200 tablets | $324.00 | $1.62 |
Every pack holds far more than one course. A 70 kg adult uses 6 tablets of 250 mg (1,500 mg) for the treatment day, so the smallest 250 mg pack of 40 tablets covers that course several times over. Our shipping page lists standard registered shipping at a flat $25, free on orders of $149 or more, with delivery to the US in 7 to 14 business days and a tracking number. Customs fees, if any, are the recipient's responsibility. Take triclabendazole only after a doctor has diagnosed the infection and set the dose.
Questions to ask your doctor
- Did the stool or blood test confirm Fasciola, and could it be a different fluke that needs another medicine?
- What is my dose per intake, rounded up to the next half tablet, and what time should I take each dose?
- Do I need an ECG before or after treatment because of my heart history, potassium level, liver health or other medicines?
- Do any of my medicines block CYP1A2 or depend on CYP2C19?
- Which symptoms after treatment, such as right-sided pain or jaundice, should make me call you?
- When should I repeat the stool test to check that the infection has cleared?
Related guides
- Praziquantel for humans (treats most other flukes, but not Fasciola)
- Nitazoxanide 500 mg (the CDC's limited-data alternative)
- Albendazole dosage guide
- Mebendazole vs albendazole for worms
- Intestinal worm treatment
- Antiparasitic medicine guide
Related products: Biltree 600 mg (praziquantel) and Nizonide 500 mg (nitazoxanide).
Sources
- EGATEN (triclabendazole) tablets, US prescribing information, Novartis Pharmaceuticals Corporation, DailyMed setid 5552884e-10ea-450c-9658-d3d4f33c946e (SPL version 12, published 8 June 2026): sections 1, 2, 3, 4, 5.1, 6.1, 6.2, 7.1, 8, 10, 11, 12, 14, 16, 17.
- US Food and Drug Administration. Drugs@FDA via openFDA: NDA 208711 (Egaten), submissions and products, accessed 27 October 2026.
- Centers for Disease Control and Prevention. Clinical Overview of Fasciola, and About Fasciola (Liver Flukes), accessed 27 October 2026.
- Centers for Disease Control and Prevention. CDC Drug Service: Our Formulary, accessed 27 October 2026.
- Centers for Disease Control and Prevention. Clinical Overview of Paragonimiasis, accessed 27 October 2026.
- World Health Organization. Foodborne trematode infections, fact sheet, accessed 27 October 2026.
- World Health Organization. Electronic Essential Medicines List: Triclabendazole, accessed 27 October 2026.
- Novartis. Novartis receives FDA approval for Egaten for the treatment of fascioliasis, a neglected tropical disease. Media release, 13 February 2019.
- Novartis. Donations (access) page: fascioliasis and paragonimiasis, accessed 27 October 2026.
- Morales ML, et al. Triclabendazole treatment failure for Fasciola hepatica infection among preschool and school-age children, Cusco, Peru. Emerg Infect Dis 2021;27(7):1850-1857. PMID 34152949.
- Cabada MM, et al. Treatment failure after multiple courses of triclabendazole among patients with fascioliasis in Cusco, Peru: a case series. PLoS Negl Trop Dis 2016;10(1):e0004361. PMID 26808543.
- Centers for Medicare and Medicaid Services. National Average Drug Acquisition Cost (NADAC), data.medicaid.gov, 2024, 2025 and 2026 files, searched for EGATEN and TRICLABENDAZOLE on 27 October 2026 (no rows).
- DailyMed. Triclabendazole bulk powder listings (Maeda Inc, setid 2f183a2f-03f6-4475-9a38-38545cc762f0; AX Pharmaceutical Corp, setid 2ebc302e-1ffd-4be4-95e6-a341251c9e06), accessed 27 October 2026.
- US Food and Drug Administration. Personal Importation, accessed 27 October 2026.
This guide is for information and does not replace advice from a doctor or pharmacist who knows your medical history. Triclabendazole should be taken only after a confirmed diagnosis and with a dose set by a prescriber.
?Frequently Asked Questions
What is triclabendazole used for in humans?
In the US, triclabendazole (Egaten) is approved for one condition: fascioliasis, an infection with the Fasciola liver fluke, in patients 6 years of age and older. The WHO also recommends it for paragonimiasis (lung fluke), which is not on the US label. It is not a general dewormer for roundworm, pinworm, hookworm or tapeworm.
What is the triclabendazole dose for adults?
The US label dose is 2 doses of 10 mg/kg given 12 hours apart, taken with food, for 20 mg/kg in total on one day. The 250 mg tablet splits into two 125 mg halves and the label says to round the dose upwards. For a 70 kg adult that works out to 750 mg (3 tablets) per dose and 6 tablets for the day.
Is triclabendazole FDA approved?
Yes. The FDA approved Egaten (triclabendazole) 250 mg tablets from Novartis on 13 February 2019 under NDA 208711, for fascioliasis in patients 6 years and older. Its marketing status is prescription. An openFDA search on 27 October 2026 found no approved generic.
Why must triclabendazole be taken with food?
Food raises absorption. In the label's data, taking a 10 mg/kg dose with a meal of about 560 kcal raised peak levels and total exposure of triclabendazole about 3-fold, and of its active sulfoxide metabolite about 2-fold, compared with fasting.
What are the common side effects of triclabendazole?
In the label's pooled studies, abdominal pain was reported by 56% of patients given 10 mg/kg once and 93% of those given 20 mg/kg in two doses. Sweating, nausea, decreased appetite, headache and hives were also common. The label says abdominal pain, biliary colic and jaundice could be partly caused by the infection, especially with a heavy worm burden.
Does triclabendazole affect the heart?
Yes, it prolongs the QTc interval. At the recommended dose the largest placebo-corrected mean increase was 9.2 msec, and at three times the approved duration it was 21.7 msec. The label advises ECG monitoring for people with QT risk factors, low potassium, liver impairment, or medicines that prolong QT or block CYP1A2, and says to stop treatment if signs of arrhythmia occur.
Who should not take triclabendazole?
The label contraindicates it in people with known hypersensitivity to triclabendazole, to other benzimidazole derivatives such as albendazole or mebendazole, or to any of the tablet's ingredients. It has not been studied in kidney or liver impairment, there are no human pregnancy data, and it is not approved for children under 6.
How well does triclabendazole work?
In the label's six open label studies of 245 patients, 95.5% of those given 20 mg/kg in two doses had no Fasciola eggs in stool at day 60. Treatment failure has been reported, including in the Cusco region of Peru, where one cohort of 146 children had a 55% cure rate after the first treatment, so a follow-up stool test is useful.
Can I use veterinary triclabendazole instead?
No. The triclabendazole powders listed on DailyMed that we checked are bulk ingredients categorized for animal drug use, not finished human tablets. A human dose depends on an accurate tablet strength and on the warnings in the human label, so only use a product made for people, as directed by a prescriber.
How do I get triclabendazole in the United States?
Egaten is a prescription medicine, so you need a doctor's diagnosis and prescription, filled through a pharmacy. The label lists Novartis (1-888-669-6682) for information. The CDC Drug Service formulary does not list triclabendazole, and the WHO donation program supplies ministries of health in endemic countries, not individual US patients.
Is it legal to import triclabendazole from India?
The FDA says that in most circumstances it is illegal for individuals to import drugs for personal use, and that a drug approved in another country but unapproved in the US is illegal to import. Its exceptions are narrow and include that effective treatment may not be available domestically. Egaten is FDA approved and marketed in the US, so check your own situation before ordering.
SafeRxPills Pharmacy Team
Pharmacist, Content, B.Pharm, M.Pharm, Rajiv Gandhi University
Pharmacist writing on antiparasitic, ophthalmic and dermatological generics. Focuses on what the regulatory labelling and published evidence actually support.
Comments (0)
Leave a Comment
No comments yet. Be the first to share your thoughts!
Related Articles

Niclosamide for Tapeworm: What It Treats, Dosage by Age, Side Effects and US Status
June 26, 2026

Praziquantel for Humans: What It Treats, Dose by Weight, Safety and US Cost
July 6, 2026

Ivermectin for Scabies: Dose by Weight, Second Dose Timing and How It Compares With Permethrin
June 16, 2026
